Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,174 across all filing types
Latest filing 2025-02-03 Legal Proceedings Report
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Action(s) taken or orders passed
Legal Proceedings Report Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about receipt of orders from Maharashtra and Delhi GST authorities imposing penalties. The document includes details of the orders, dates, alleged violations, and the company's response. It is a regulatory announcement about legal or compliance matters, not a full audit report or annual report. It does not contain financial statements or detailed financial analysis. The document is about legal proceedings or regulatory actions involving the company. Therefore, it fits best under Legal Proceedings Report (LTR). The document length is 4774 characters, which is sufficient for a detailed announcement but not a full report like 10-K or IR. Hence, the classification is LTR with high confidence.
2025-02-03 English
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Legal Proceedings Report Classification · 95% confidence The document is a disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about receipt of orders from Maharashtra and Delhi GST authorities imposing penalties. The document includes details of the orders, alleged violations, and the company's response. It is a regulatory announcement about legal or compliance matters, not a full audit report or financial statement. The document is about legal proceedings or regulatory actions involving the company, fitting the category of Legal Proceedings Report (LTR). The document length is 4774 characters, which is sufficient to contain substantive information rather than a mere announcement. Therefore, the classification is LTR with high confidence.
2025-02-03 English
Lupin Announces Closure of Inspection by U.S. FDA at its Somerset Facility with No Observations.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a U.S. FDA Pre-Approval Inspection at Lupin Limited's manufacturing facility with no observations. It is addressed to stock exchanges and references compliance with SEBI Listing Regulations. The content is an announcement of an event related to regulatory inspection results, not a financial report, management change, or detailed financial data. The document length is 3860 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial statements, earnings data, or detailed management discussion. Therefore, this document fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2025-02-01 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a U.S. FDA Pre-Approval Inspection at Lupin's manufacturing facility with no observations. It is a regulatory disclosure pursuant to SEBI Listing Obligations and Disclosure Requirements, 2015, Regulation 30, which pertains to material events or information. The document does not contain financial statements, detailed financial analysis, or management discussion. It is an announcement of an event related to regulatory inspection results, not a financial report or detailed management report. The document length is 3860 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-01 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the allotment of shares under the company's Employee Stock Option Plan (ESOP). It specifies the number of shares allotted, the increase in issued and paid-up share capital, and references compliance with SEBI Listing Regulations. The document is short (1936 characters) and serves as an announcement of a capital change due to share allotment. It does not contain financial statements or detailed financial analysis, nor is it a report or presentation. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2025-01-30 English
Intimation regarding allotment of 246462 shares under ESOP.
Share Issue/Capital Change Classification · 100% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) disclosing the allotment of shares under the company's Employee Stock Option Plan (ESOP). It mentions the increase in issued and paid-up share capital due to the allotment of fully paid-up equity shares upon exercising vested options. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(2), which pertains to disclosure of material events. The content is an announcement of a capital change (allotment of shares) rather than a financial report or detailed analysis. The document length is short (1936 characters), and it is clearly an announcement of a share capital change due to ESOP exercise. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2025-01-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.